Goldman Sachs’s Cymabay Therapeutics CBAY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-630,735
Closed -$14.9M 5981
2023
Q4
$14.9M Buy
630,735
+69,974
+12% +$1.25M ﹤0.01% 2179
2023
Q3
$8.36M Sell
560,761
-12,384
-2% -$164K ﹤0.01% 2543
2023
Q2
$6.28M Sell
573,145
-200,201
-26% -$1.86M ﹤0.01% 2900
2023
Q1
$6.74M Buy
773,346
+688,132
+808% +$5.51M ﹤0.01% 2772
2022
Q4
$534K Sell
85,214
-149,508
-64% -$568K ﹤0.01% 4836
2022
Q3
$822K Sell
234,722
-20,321
-8% -$73K ﹤0.01% 4647
2022
Q2
$753K Sell
255,043
-309,073
-55% -$738K ﹤0.01% 4816
2022
Q1
$1.75M Buy
564,116
+136,996
+32% +$431K ﹤0.01% 4364
2021
Q4
$1.44M Buy
427,120
+284,156
+199% +$1.08M ﹤0.01% 4530
2021
Q3
$522K Buy
142,964
+601
+0.4% +$2.37K ﹤0.01% 5169
2021
Q2
$621K Buy
142,363
+49,595
+53% +$220K ﹤0.01% 5095
2021
Q1
$421K Sell
92,768
-848,214
-90% -$4.57M ﹤0.01% 5239
2020
Q4
$5.4M Buy
940,982
+850,404
+939% +$6.44M ﹤0.01% 2949
2020
Q3
$655K Sell
90,578
-624,397
-87% -$3.34M ﹤0.01% 4333
2020
Q2
$2.5M Sell
714,975
-7,526
-1% -$21.7K ﹤0.01% 3294
2020
Q1
$1.07M Buy
722,501
+342,100
+90% +$574K ﹤0.01% 3706
2019
Q4
$746K Buy
380,401
+121,371
+47% +$456K ﹤0.01% 4295
2019
Q3
$1.33M Buy
259,030
+118,278
+84% +$716K ﹤0.01% 3836
2019
Q2
$1.01M Sell
140,752
-68,743
-33% -$778K ﹤0.01% 3994
2019
Q1
$2.78M Buy
209,495
+114,946
+122% +$1.22M ﹤0.01% 3386
2018
Q4
$744K Buy
94,549
+29,041
+44% +$276K ﹤0.01% 4147
2018
Q3
$726K Buy
65,508
+5,211
+9% +$64.7K ﹤0.01% 4216
2018
Q2
$809K Sell
60,297
-382,046
-86% -$4.78M ﹤0.01% 4217
2018
Q1
$5.75M Buy
442,343
+420,936
+1,966% +$5.23M ﹤0.01% 2780
2017
Q4
$197K Buy
+21,407
New +$183K ﹤0.01% 5434
2016
Q4
Sell
-16,554
Closed -$32K 7140
2016
Q3
$32K Buy
+16,554
New +$32.9K ﹤0.01% 6624
2015
Q1
Sell
-42,563
Closed -$418K 7338
2014
Q4
$418K Buy
+42,563
New +$342K ﹤0.01% 5458

Other funds holding CBAY